XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 34 filers reported holding XILIO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $478,377 | -19.6% | 226,719 | -0.2% | 0.00% | – |
Q2 2023 | $595,283 | -17.4% | 227,207 | -0.0% | 0.00% | – |
Q1 2023 | $720,465 | +14.9% | 227,276 | -2.5% | 0.00% | – |
Q4 2022 | $626,953 | +3199.8% | 233,068 | +8826.4% | 0.00% | – |
Q1 2022 | $19,000 | -75.0% | 2,611 | -45.3% | 0.00% | – |
Q4 2021 | $76,000 | – | 4,774 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RiverVest Venture Management LLC | 1,441,444 | $10,191,000 | 10.46% |
AJU IB Investment Co., Ltd. | 667,742 | $4,721,000 | 7.29% |
Atlas Venture Life Science Advisors, LLC | 2,759,344 | $19,509,000 | 2.47% |
Bain Capital Life Sciences Investors, LLC | 2,805,413 | $19,834,000 | 1.93% |
Soleus Capital Management, L.P. | 477,495 | $3,376,000 | 0.44% |
Monashee Investment Management LLC | 163,066 | $1,153,000 | 0.33% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,078,692 | $14,696,000 | 0.33% |
RA Capital Management | 2,002,217 | $14,156,000 | 0.31% |
HARVARD MANAGEMENT CO INC | 416,059 | $2,942,000 | 0.30% |
Rock Springs Capital Management LP | 1,191,094 | $8,421,000 | 0.21% |